Department of Neuropsychiatry, Seoul National University Bundang Hospital, Seongnam, South Korea; Department of Psychiatry, Seoul National University, College of Medicine, Seoul, South Korea.
Department of Laboratory Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.
Clin Nutr. 2021 Jul;40(7):4579-4584. doi: 10.1016/j.clnu.2021.05.034. Epub 2021 Jun 9.
Hyperhomocysteinemia has been repeatedly found to increase the risk of dementia. However, the effects of hypohomocysteinemia on the risk of dementia have been barely investigated. If hypohomocysteinemia, like hyperhomocysteinemia, increases the risk of dementia, misuse or overuse of homocysteine-lowing agents such as vitamin supplements may increase the risk of dementia.
To investigate whether hypohomocysteinemia, like hyperhomocysteinemia, could increase the risk of dementia and Alzheimer's disease (AD) in a large population-based cohort of older adults.
This prospective cohort study followed 2655 randomly sampled, community-dwelling, non-demented individuals aged 60 years or older from 2010 to 2018. We measured baseline serum total homocysteine (tHcy) levels and examined the effect of serum tHcy on the risks of dementia and AD using Cox proportional hazards models.
During the follow-up period (mean = 5.4 years, SD = 0.9), dementia and AD developed in 85 and 64 participants, respectively. Not only the participants with high serum tHcy (≥10.6 μmol/L) but also those with low serum tHcy (≤8.9 μmol/L) were 4-5 times more likely to develop dementia and AD compared to those with serum tHcy levels between 9.0 and 10.5 μmol/L. With the increase in serum tHcy concentration, the use of vitamin supplements decreased, and 41.2% of the participants with low serum tHcy (≤8.9 μmol/L) were taking vitamin supplements.
Not only hyperhomocysteinemia but also hypohomocysteinemia considerably increased the risk of dementia and AD in older adults. The risk of dementia that results from overuse or misuse of vitamin supplements should be acknowledged and homocysteine-lowering health policies should be tailored to consider dementia risks that are associated with hypohomocysteinemia.
高同型半胱氨酸血症已被反复发现会增加痴呆的风险。然而,低同型半胱氨酸血症对痴呆风险的影响几乎没有被研究过。如果低同型半胱氨酸血症像高同型半胱氨酸血症一样增加痴呆的风险,那么过度使用或滥用降低同型半胱氨酸的药物(如维生素补充剂)可能会增加痴呆的风险。
在一个大型的老年人群队列中,调查低同型半胱氨酸血症是否像高同型半胱氨酸血症一样会增加痴呆和阿尔茨海默病(AD)的风险。
这项前瞻性队列研究从 2010 年至 2018 年,对 2655 名随机抽取的、居住在社区的、无痴呆的 60 岁及以上老年人进行了随访。我们测量了基线血清总同型半胱氨酸(tHcy)水平,并使用 Cox 比例风险模型检查了血清 tHcy 对痴呆和 AD 风险的影响。
在随访期间(平均=5.4 年,SD=0.9),85 名参与者发生了痴呆,64 名参与者发生了 AD。与血清 tHcy 水平在 9.0 至 10.5 μmol/L 之间的参与者相比,不仅高血清 tHcy(≥10.6 μmol/L)的参与者,而且低血清 tHcy(≤8.9 μmol/L)的参与者发生痴呆和 AD 的可能性也高出 4-5 倍。随着血清 tHcy 浓度的增加,维生素补充剂的使用减少,而 41.2%的低血清 tHcy(≤8.9 μmol/L)参与者正在服用维生素补充剂。
不仅高同型半胱氨酸血症,而且低同型半胱氨酸血症都会显著增加老年人患痴呆和 AD 的风险。过度使用或滥用维生素补充剂导致的痴呆风险应该得到承认,降低同型半胱氨酸的健康政策应该根据与低同型半胱氨酸血症相关的痴呆风险进行调整。